Severe COVID-19 infection: An institutional review and literature overview

被引:0
|
作者
Akpoviroro, Ogheneyoma [1 ]
Sauers, Nathan Kyle [2 ]
Uwandu, Queeneth [1 ]
Castagne, Myriam [3 ]
Akpoviroro, Oghenetejiro Princess [4 ]
Humayun, Sara [1 ]
Mirza, Wasique [1 ]
Woodard, Jameson [1 ]
机构
[1] Geisinger Wyoming Valley Med Ctr, Dept Internal Med, Wilkes Barre, PA 18711 USA
[2] Penn State Univ, Dept Engn, State Coll, PA USA
[3] Boston Univ, Clin & Translat Sci Inst, Boston, MA USA
[4] Mater Dei Hosp, Dept Med, Msida, Malta
来源
PLOS ONE | 2024年 / 19卷 / 08期
关键词
ANGIOTENSIN-CONVERTING ENZYME; INVASIVE MECHANICAL VENTILATION; CONGESTIVE-HEART-FAILURE; OBSTRUCTIVE SLEEP-APNEA; CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; SARS CORONAVIRUS; UNITED-STATES; LIVER-INJURY; AZITHROMYCIN;
D O I
10.1371/journal.pone.0304960
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Our study aimed to describe the group of severe COVID-19 patients at an institutional level, and determine factors associated with different outcomes. Methods A retrospective chart review of patients admitted with severe acute hypoxic respiratory failure due to COVID-19 infection. Based on outcomes, we categorized 3 groups of severe COVID-19: (1) Favorable outcome: progressive care unit admission and discharge (2) Intermediate outcome: ICU care (3) Poor outcome: in-hospital mortality. Results Eighty-nine patients met our inclusion criteria; 42.7% were female. The average age was 59.7 (standard deviation (SD):13.7). Most of the population were Caucasian (95.5%) and non-Hispanic (91.0%). Age, sex, race, and ethnicity were similar between outcome groups. Medicare and Medicaid patients accounted for 62.9%. The average BMI was 33.5 (SD:8.2). Moderate comorbidity was observed, with an average Charlson Comorbidity index (CCI) of 3.8 (SD:2.6). There were no differences in the average CCI between groups(p = 0.291). Many patients (67.4%) had hypertension, diabetes (42.7%) and chronic lung disease (32.6%). A statistical difference was found when chronic lung disease was evaluated; p = 0.002. The prevalence of chronic lung disease was 19.6%, 27.8%, and 40% in the favorable, intermediate, and poor outcome groups, respectively. Smoking history was associated with poor outcomes (p = 0.04). Only 7.9% were fully vaccinated. Almost half (46.1%) were intubated and mechanically ventilated. Patients spent an average of 12.1 days ventilated (SD:8.5), with an average of 6.0 days from admission to ventilation (SD:5.1). The intermediate group had a shorter average interval from admission to ventilator (77.2 hours, SD:67.6), than the poor group (212.8 hours, SD:126.8); (p = 0.001). The presence of bacterial pneumonia was greatest in the intermediate group (72.2%), compared to the favorable group (17.4%), and the poor group (56%); this was significant (p<0.0001). In-hospital mortality was seen in 28.1%. Conclusion Most patients were male, obese, had moderate-level comorbidity, a history of tobacco abuse, and government-funded insurance. Nearly 50% required mechanical ventilation, and about 28% died during hospitalization. Bacterial pneumonia was most prevalent in intubated groups. Patients who were intubated with a good outcome were intubated earlier during their hospital course, with an average difference of 135.6 hours. A history of cigarette smoking and chronic lung disease were associated with poor outcomes.
引用
收藏
页数:34
相关论文
共 50 条
  • [41] Bilateral Lung Transplantation after Severe COVID-19 Infection. Single Institutional Experience
    Acho, Christine
    D'Attellis, Nicola
    Rampolla, Reinaldo
    Catarino, Pedro
    Megna, Dominick
    Emerson, Dominic
    Granflor, Eliza
    Chan, Alice
    Nassem, Tariq
    ANESTHESIA AND ANALGESIA, 2022, 134 : 90 - 91
  • [42] Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review
    Dai, Jinghong
    Xiong, Yali
    Li, Hui
    Qian, Yajun
    Xu, Ying
    Xu, Qingqing
    Yan, Xin
    Tang, Jian
    CLINICAL RHEUMATOLOGY, 2020, 39 (07) : 2031 - 2037
  • [43] Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review
    Jinghong Dai
    Yali Xiong
    Hui Li
    Yajun Qian
    Ying Xu
    Qingqing Xu
    Xin Yan
    Jian Tang
    Clinical Rheumatology, 2020, 39 : 2031 - 2037
  • [44] Severe COVID-19 Pneumonia and Genetic Susceptibility: A Case Report and Literature Review
    Alsayed, Badr A.
    Mir, Rashid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [45] Cutaneous Reactions of COVID-19 Infection and COVID-19 Vaccines - a Review
    Singal, Amit
    Desai, Amar D.
    Lipner, Shari R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB31 - AB31
  • [46] COVID-19 and skin manifestations: overview of current literature
    Lange, Kristin
    Matthies, Maja
    Firouzi-Memarpuri, Parnian
    Homey, Bernhard
    HAUTARZT, 2022, 73 (04): : 291 - 297
  • [47] COVID-19 and Dentistry in 72 Questions: An Overview of the Literature
    Derruau, Stephane
    Bouchet, Jerome
    Nassif, Ali
    Baudet, Alexandre
    Yasukawa, Kazutoyo
    Lorimier, Sandrine
    Precheur, Isabelle
    Bloch-Zupan, Agnes
    Pellat, Bernard
    Chardin, Helene
    Jung, Sophie
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 45
  • [48] Fulminant Myocarditis and Cardiogenic Shock Following COVID-19 Infection Versus COVID-19 Vaccination: A Systematic Literature Review
    Guglin, Maya E.
    Etuk, Aniekeme
    Shah, Chirag
    Ilonze, Onyedika J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
  • [49] Severe scald injury in a patient with severe COVID-19 infection
    Stoegner, V-A
    Dieck, T.
    Vogt, P. M.
    Krezdorn, N.
    ANASTHESIOLOGIE & INTENSIVMEDIZIN, 2021, 62 : 522 - 526
  • [50] Overview of COVID-19 Infection, Treatment, and Prevention in Children
    Kao, Carol M.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)